Interestingly, ROS has been reported to exert both activating and inhibitory effects on PTEN and AKT signaling in prostate cancer DU‐145 cells and acute myeloid leukemia cells [55, 56]. This evidence concerns the gene AKT1 and acute myeloid leukemia.